---
title: "Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002275.SZ.md"
symbol: "002275.SZ"
name: "Guilin Sanjin Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-03-14T09:45:48.135Z"
locales:
  - [en](https://longbridge.com/en/quote/002275.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002275.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002275.SZ.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/002275.SZ.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002275.SZ.md)


# Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ)

## Company Overview

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache capsule, compound panax notoginseng stomach pain tablets, Sanqi xueshangning capsules, Sanqi xueshangning powder, compound luo han guo qing fei granules, compound luo han guo lung clearing syrup, compound red root tablets, Shuanghu zhongtongning, liver and kidney tonic granules, and jade leaf detoxification granules. Its products are used in various therapeutic areas, such as urinary system disease, oral and throat, cardiovascular and cerebrovascular disease, neurological diseases, respiratory disease, digestive system disease, internal medicine, musculoskeletal system diseases, and tonic drugs.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.sanjin.com.cn](https://www.sanjin.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-14T04:30:12.000Z

**Overall: B (0.39)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 38 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -1.56% |  |
| Net Profit YoY | 28.07% |  |
| P/B Ratio | 2.53 |  |
| Dividend Ratio | 3.93% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8219845385.84 |  |
| Revenue | 2081525858.51 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 16.71% | A |
| Profit Margin | 25.12% | A |
| Gross Margin | 74.12% | A |
| Revenue YoY | -1.56% | D |
| Net Profit YoY | 28.07% | B |
| Total Assets YoY | 9.29% | B |
| Net Assets YoY | 7.66% | B |
| Cash Flow Margin | 398.10% | C |
| OCF YoY | -1.56% | D |
| Turnover | 0.51 | C |
| Gearing Ratio | 24.53% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Guilin Sanjin Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-1.56%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "28.07%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.53",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.93%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8219845385.84",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2081525858.51",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "16.71%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "25.12%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "74.12%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-1.56%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "28.07%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.29%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.66%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "398.10%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-1.56%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.51",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "24.53%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 15.72 | 17/222 | 17.42 | 16.78 | 16.08 |
| PB | 2.53 | 109/222 | 2.81 | 2.73 | 2.63 |
| PS (TTM) | 3.95 | 95/222 | 4.17 | 4.07 | 3.89 |
| Dividend Yield | 3.93% | 15/222 | 4.05% | 3.94% | 3.81% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 04 | Salubris (002294.SZ) | B | B | C | A | B | B |
| 05 | Haisco (002653.SZ) | B | C | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-06-03T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.99 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002275.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002275.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002275.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002275.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**